Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 11/20 | 0.72 |
| ▸ | HDAC1 | Q13547 | 16/20 | 0.66 |
| ▸ | HDAC3 | O15379 | 11/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.66 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.64 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.64 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.64 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.64 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.64 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.64 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.64 |
| ▸ | HDAC9 | Q9UKV0 | 4/20 | 0.64 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.64 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | STAT3 | P40763 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30864183 | 1.00 | HDAC2 (0.72) | HDAC2HDAC1HDAC3MAPK1PTGS1 | |
| SCHEMBL5187749 | 0.91 | HDAC1 (0.74) | HDAC2HDAC1HDAC3MAPK1PTGS1 | |
| SCHEMBL1060598 | 0.91 | HDAC1 (0.79) | HDAC2HDAC1HDAC3MAPK1PTGS1 | |
| SCHEMBL8401704 | 0.85 | HDAC1 (0.89) | HDAC2HDAC1HDAC3MAPK1PTGS1 | |
| SCHEMBL5224340 | 0.84 | HDAC1 (0.61) | HDAC2HDAC1HDAC3MAPK1PTGS1 | |
| SCHEMBL8352548 | 0.82 | HDAC1 (0.66) | HDAC2HDAC1HDAC3MAPK1PTGS1 | |
| SCHEMBL12841849 | 0.81 | HDAC1 (0.76) | HDAC2HDAC1HDAC3MAPK1PTGS1 | |
| SCHEMBL2074828 | 0.81 | HDAC1 (0.65) | HDAC2HDAC1HDAC3MAPK1PTGS1 | |
| SCHEMBL2411669 | 0.81 | HDAC1 (0.69) | HDAC2HDAC1HDAC3HDAC8HDAC6 | |
| Dinaline SCHEMBL29354254 | 0.80 | HDAC1 (0.79) | HDAC2HDAC1HDAC3MAPK1PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117777096-A | Preparation method of zee Bei Nuosi his | 江西师范大学 | 2024-03-29 | — | — | CN | disclosed |
| US-8735429-B2 | Benzamide compounds useful as histone deacetylase inhibitors | ASTRAZENECA AB (SE) | 2014-05-27 | — | — | US | disclosed |
| EP-1954690-B1 | BENZAMIDE COMPOUNDS USEFUL AS HISTONE DEACETYLASE INHIBITORS | ASTRAZENECA AB (SE) | 2013-05-15 | — | — | EP | disclosed |
| US-20120225907-A1 | BENZAMIDE COMPOUNDS USEFUL AS HISTONE DEACETYLASE INHIBITORS | ASTRAZENECA AB (SE) | 2012-09-06 | — | — | US | disclosed |
| EP-1495002-B1 | BENZAMIDE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS | ASTRAZENECA AB (SE) | 2012-09-05 | — | — | EP | disclosed |
| US-8247562-B2 | Benzamide derivatives useful as histone deacetylase inhibitors | ASTRAZENECA AB (SE) | 2012-08-21 | — | — | US | disclosed |
| US-8207202-B2 | N-(2-aminophenyl)-4-{1-[(5-methoxy-1,3-dimethyl-1H-pyrazol-4-yl)methyl]piperidin-4-yl}benzamide, for example; use as an antiproliferative agent in the prevention or treatment of tumors or other proliferative conditions, which are sensitive to the inhibition of histone deacetylase | ASTRAZENECA AB (SE) | 2012-06-26 | — | — | US | disclosed |
| US-8207202-B2 | N-(2-aminophenyl)-4-{1-[(5-methoxy-1,3-dimethyl-1H-pyrazol-4-yl)methyl]piperidin-4-yl}benzamide, for example; use as an antiproliferative agent in the prevention or treatment of tumors or other proliferative conditions, which are sensitive to the inhibition of histone deacetylase | ASTRAZENECA AB (SE) | 2012-06-26 | — | — | US | disclosed |
| US-20100331329-A1 | BENZAMIDE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS | ASTRAZENECA AB (SE) | 2010-12-30 | — | — | US | disclosed |
| US-20090029991-A1 | BENZAMIDE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | US | disclosed |
| US-20080269294-A1 | N-(2-aminophenyl)-4-{1-[(5-methoxy-1,3-dimethyl-1H-pyrazol-4-yl)methyl]piperidin-4-yl}benzamide, for example; use as an antiproliferative agent in the prevention or treatment of tumors or other proliferative conditions, which are sensitive to the inhibition of histone deacetylase | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | disclosed |
| US-20080269294-A1 | N-(2-aminophenyl)-4-{1-[(5-methoxy-1,3-dimethyl-1H-pyrazol-4-yl)methyl]piperidin-4-yl}benzamide, for example; use as an antiproliferative agent in the prevention or treatment of tumors or other proliferative conditions, which are sensitive to the inhibition of histone deacetylase | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | disclosed |
| WO-2007045844-A1 | BENZAMIDE COMPOUNDS USEFUL AS HISTONE DEACETYLASE INHIBITORS | ASTRAZENECA AB (SE) | 2007-04-26 | — | — | WO | disclosed |
| US-20050171103-A1 | Benzamide derivatives useful as histone deacetylase inhibitors | ASTRAZENECA AB (SE) | 2005-08-04 | — | — | US | disclosed |
| EP-1495002-A1 | BENZAMIDE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS | Astrazeneca AB (SE) | 2005-01-12 | — | — | EP | disclosed |
| WO-2003087057-A1 | BENZAMIDE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS | ASTRAZENECA AB (SE) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225907-A1 | BENZAMIDE COMPOUNDS USEFUL AS HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HDAC5 | HDAC2 4/4885HDAC1 1/4885HDAC3 5/4885 |
| US-20080269294-A1 | N-(2-aminophenyl)-4-{1-[(5-methoxy-1,3-dimethyl-1H-pyrazol-4-yl)methyl]piperidin-4-yl}benzamide, for example; use as an antiproliferative agent in the prevention or treatment of tumors or other proliferative conditions, which are sensitive to the inhibition of histone deacetylase | HDAC1, HDAC5, HDAC2 | HDAC2 3/4885HDAC1 1/4885HDAC3 5/4885 |
| US-20050171103-A1 | Benzamide derivatives useful as histone deacetylase inhibitors | HDAC3, HDAC1, HDAC4 | HDAC2 5/4885HDAC1 2/4885HDAC3 1/4885 |
| US-20090029991-A1 | BENZAMIDE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC3, HDAC2 | HDAC2 3/4885HDAC1 1/4885HDAC3 2/4885 |
| US-20100331329-A1 | BENZAMIDE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC1, HDAC4 | HDAC2 5/4885HDAC1 2/4885HDAC3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.